Principal Financial Group Inc. Sells 112,303 Shares of Integra LifeSciences Holdings Corporation $IART

Principal Financial Group Inc. trimmed its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 25.6% during the 1st quarter, HoldingsChannel.com reports. The firm owned 325,643 shares of the life sciences company’s stock after selling 112,303 shares during the quarter. Principal Financial Group Inc.’s holdings in Integra LifeSciences were worth $3,068,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Rubric Capital Management LP raised its stake in shares of Integra LifeSciences by 1.3% in the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after purchasing an additional 100,000 shares during the last quarter. Invesco Ltd. increased its holdings in Integra LifeSciences by 0.9% in the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock worth $43,754,000 after buying an additional 31,931 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Integra LifeSciences by 9.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock worth $45,634,000 after buying an additional 267,134 shares in the last quarter. State Street Corp raised its position in Integra LifeSciences by 0.8% in the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after buying an additional 21,717 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY raised its position in Integra LifeSciences by 5.3% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock worth $33,099,000 after buying an additional 135,198 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

Key Stories Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra reported second-quarter adjusted EPS of $0.56, above the $0.48 analyst consensus and up from $0.45 a year earlier. Revenue of $418.8 million was slightly ahead of the $417.5 million estimate. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year 2026 EPS guidance of $2.40 to $2.50 centers on $2.45, matching consensus, while revenue guidance of approximately $1.7 billion remains in line with expectations. Third-quarter revenue guidance of $410 million to $425 million also brackets the $417.3 million consensus estimate. Integra Q2 2026 Earnings Call Transcript
• Neutral Sentiment: UBS initiated coverage with a Neutral rating and a $19 price target, implying potential upside from recent trading levels but signaling that the valuation and operating outlook appear broadly balanced. UBS coverage report
• Neutral Sentiment: Technical screens identified IART as a potential breakout stock trading near its 52-week high, which may attract momentum-focused investors; however, this does not change the company’s fundamental outlook. Stocks Showing Breakout Potential
• Negative Sentiment: The earnings beat was relatively modest at the revenue level, and the company continues to report a negative net margin. With quarterly and full-year guidance essentially matching expectations rather than being raised materially, investors may have viewed the update as lacking a significant upside catalyst, contributing to the stock’s decline.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on IART shares. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Thursday, June 18th. Wall Street Zen cut shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a research report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price objective on the stock. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Finally, Wells Fargo & Company lifted their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $18.43.

Integra LifeSciences Trading Down 16.5%

NASDAQ:IART opened at $16.49 on Thursday. Integra LifeSciences Holdings Corporation has a one year low of $8.70 and a one year high of $20.49. The business has a fifty day moving average price of $17.63 and a 200-day moving average price of $13.42. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -2.55, a price-to-earnings-growth ratio of 1.37 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Sell-side analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.